SCHEDULE: Perceptive Advisors Discloses 9.99% Stake in Palisade Bio

Perceptive Advisors LLC and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc., totaling 12,243,018 shares.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their ownership in Palisade Bio, Inc.
• The Reporting Persons beneficially own an aggregate of 12,243,018 shares of Palisade Bio, Inc. Common Stock.
• This ownership represents 9.99% of the company's outstanding Common Stock.
• The ownership percentage is calculated based on 96,645,431 outstanding shares reported by the Issuer, plus 25,714,285 additional shares issued from an underwriters' over-allotment option exercise on October 6, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds 12,050,000 shares of Common Stock and 5,185,714 Pre-Funded Warrants.
• Due to a beneficial ownership limitation, only 193,018 shares from the Pre-Funded Warrants are currently exercisable, preventing ownership from exceeding 9.99% of the outstanding shares.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.

Sentiment

Score: 7

Explanation: The disclosure of a 9.99% beneficial ownership stake by Perceptive Advisors, a prominent life sciences investment firm, is a positive signal. It suggests institutional confidence in Palisade Bio, Inc., which can be viewed favorably by the market. The investment includes both common stock and pre-funded warrants, indicating a strategic interest.

Positives

• A significant stake (9.99%) by a prominent life sciences investment firm, Perceptive Advisors, indicates confidence in Palisade Bio, Inc.'s prospects.
• The investment includes both common stock and pre-funded warrants, suggesting a strategic and potentially long-term interest in the company.

Negatives

• The beneficial ownership limitation of 9.99% restricts the immediate exercise of all pre-funded warrants, potentially limiting the investor's ability to fully convert their warrants if the stock price rises significantly.

Risks

• The beneficial ownership limitation prevents the Reporting Persons from exercising all their Pre-Funded Warrants if it would result in ownership exceeding 9.99% of the outstanding Common Stock, which could cap their potential upside from these warrants.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Palisade Bio, Inc. or the Reporting Persons regarding the company's future performance or strategic direction, beyond the disclosure of their current investment.

Industry Context

Perceptive Advisors is a well-known investment firm specializing in the life sciences sector. Their significant stake in Palisade Bio, a biotechnology company, suggests a belief in the company's long-term prospects within the competitive and innovation-driven biotech industry. Such an investment by a specialized fund can be seen as a validation of the company's potential, aligning with broader trends of institutional investment in promising life sciences ventures.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor may increase confidence among existing and potential shareholders, potentially leading to positive share price movement.
• Company Management: The presence of a large, specialized investor like Perceptive Advisors could bring increased scrutiny or strategic input, potentially influencing corporate decisions.

Key Dates

Recommendation

The filing indicates a significant institutional investment by Perceptive Advisors, a respected life sciences fund, which is generally a positive indicator. However, a Schedule 13G filing primarily discloses ownership and does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial reports from Palisade Bio, Inc. to make a more informed decision, while acknowledging the positive signal from this institutional backing.

Keywords

Palisade Bio, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology, Investment